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Background. Multiple modalities have been used in the treatment of melasma with variable success. Niacinamide has anti-
inﬂammatory properties and is able to decrease the transfer of melanosomes. Objective. To evaluate the therapeutic eﬀect of
topical niacinamide versus hydroquinone (HQ) in melasma patients. Patients and Methods. Twenty-seven melasma patients were
randomized to receive for eight weeks 4% niacinamide cream on one side of the face, and 4% HQ cream on the other. Sunscreen
was applied along the observation period. They were assessed by noninvasive techniques for the evaluation of skin color, as well as
subjective scales and histological sections initially and after the treatment with niacinamide. Results. All patients showed pigment
improvement with both treatments. Colorimetric measures did not show statistical diﬀerences between both sides. However, good
to excellent improvement was observed with niacinamide in 44% of patients, compared to 55% with HQ. Niacinamide reduced
importantly the mast cell inﬁltrate and showed improvement of solar elastosis in melasma skin. Side eﬀects were present in 18%
with niacinamide versus 29% with HQ. Conclusion. Niacinamide induces a decrease in pigmentation, inﬂammatory inﬁltrate, and
solar elastosis. Niacinamide is a safe and eﬀective therapeutic agent for this condition.
1.Introduction
Melasma is deﬁned as an acquired chronic hypermelanosis
on sun exposed areas being most frequently found in
women with III-V phototypes of Fitzpatrick. The etiology is
not completely elucidated; however, the ultraviolet sunlight
exposure appears to be the most signiﬁcant factor [1]. The
basis of the treatment is photoprotection. Diverse modalities
in drug therapy have been used such as hydroquinone (HQ),
which inhibits the tyrosinase enzyme activity. In spite of
its serious adverse eﬀects and moderate results in 80% of
patients, HQ is considered the gold standard treatment in
melasma although usually relapses after suspension [2].
Niacinamide studies have demonstrated a suppression of
melanosome transfer suggesting the reduction of cutaneous
pigmentation [3], but to date there has been no clinical
report of this eﬀect in melasma. There have been several
reports regarding other beneﬁcial eﬀects of topical niaci-
namide on the skin, including prevention of photoimmuno-
suppressionandphotocarcinogenesis[4],anti-inﬂammatory
eﬀects in acne [5], rosacea [6], and psoriasis [7]. It also
increases biosynthesis of ceramides, as well as other stratum2 Dermatology Research and Practice
Figure 1: Right side treated with niacinamide. View at onset and 8 weeks later with an excellent decrease in pigmentation.
Figure 2: Left side treated with HQ: Onset and 8 weeks later with an excellent improvement.
corneum lipids with enhanced epidermal permeability bar-
rier function [8]. Moreover, its antiaging eﬀects have been
demonstrated in randomized trials [9].
The guidelines to clinical trials in melasma have sug-
gested a correct diagnosis by using at least two subjective
methods (besides an objective method), a comparison with
the therapeutic gold standard and an evaluation of safety
outcome [10].
The aim of this work was to assess the eﬃcacy and
safety of niacinamide 4% versus HQ 4% in the treatment of
melasma through subjective and objective methods.
2. Patientsand Methods
This is a double-blind, left-right randomized clinical trial.
The protocol was reviewed and approved by the ethic
committee in our hospital, and each subject signed a written
informed consent. The sample size was determined based
on favorable response: 0.8 for HQ and at least 0.4 for
niacinamide, with 95% IC, two tails, α of 0.05 and β of 0.8.
We included 27 women with melasma attending the
outpatientclinicofDermatologyDepartmentattheHospital
Central “Dr. Ignacio Morones Prieto”, from March 2008 to
February 2009.
Our inclusion criteria were women at least 18 years old
without any topical, systemic, laser, and surgical treatment
on face during the previous year. The exclusion criteria
were pregnant and nursing women, patients with history of
hypersensitivity to some of the components of the formulas
of the study, and coexistence of associate diseases and other
pigmentation diseases.
A history was taken from each patient, regarding age,
gender, occupation, time of onset, history of pregnancy, con-
traceptive pills, and sun exposure.
At baseline, we obtained two 2mm biopsies in 27 pa-
tients, one biopsy from lesioned and another one from facialDermatology Research and Practice 3
notphotoexposedskin;thesewerestainedwithhaematoxylin
and eosin todetermine the general histopathological features
of the epidermis and dermis.
The inﬂammatory inﬁltrate was counted manually by
two independent blinded observers, using a 0.5 × 0.5mm
ocular grid and 100× magniﬁcation. The cells were counted
fortheentiresection,andtheresultsexpressedasthenumber
ofcellspermm2.Thesameprocedurewasemployedtocount
melanocytes (Fontana Masson) and metachromatic granules
(Wright-Giemsa) in mast cells. To count the epidermal
melanin, we obtained a magniﬁcation of 40× to get a
scanning view of the epidermis. Images were obtained from
the entire 2 mm sample with a digital camera mounted
on a microscope (Olympus CX 31) which was connected
to a personal computer (PC). The image signals taken by
the PC were evaluated using Image-Pro Plus Version 4.5
(Media Cybernetics, Silver Spring, MA, USA). With the aim
of discern possible abnormalities of melanin in melasma
patients as shown before [11], or even being induced by the
intervention, we perform a qualitative analysis by Raman
spectrophotometry (Horiba, Jobin-Yvon T64000. Edison,
NJ, USA) before and at the conclusion of the study.
Patients were randomized in a double-blind manner to
receive one treatment on the left and the other on the
right side of the face. They received two containers labeled
right or left with 4% niacinamide (Nicomide-T cream 4%,
DUSA Pharmaceuticals Inc.) or 4% HQ (Eldoquin cream
4%, Valeant Pharmaceutical). All patients were instructed to
apply the correct amount of both treatments and to use a
SPF 50+ broad spectrum sunscreen every 3 hours during day
time.
Concomitant use of other skin care products or systemic
treatments was not allowed during the study. Treatment
was administered for the period of 8 weeks, with basal
evaluation and followup at 4 and 8 weeks. Assessments
included a skin pigment evaluation by a chromameter (CR-
300;Minolta,Osaka,Japan),melasmaareaandseverityindex
(MASI), physician global assessment (PGA) by an inde-
pendent observer, conventional photography, and infrared
thermography (Flexcam S, Infrared solutions, USA) with
photographic register which mainly was used to detect irri-
tation. All side-eﬀects were registered. The double-blinded
study was opened at 8 weeks in order to take a 2 mm biopsy
in the side treated with niacinamide.
For statistical analysis, we used the Student t-test and X2,
and a P value of less than 0.05 was considered signiﬁcant.
3. Results
Twenty-seven female patients with melasma were included,
12 (33%) were of skin phototype IV, and 13 (48%) of type V.
The pattern of melasma was centrofacial in 13 (50%), malar
in 10 (37%), and mandibular in 4 (14%).
The patients age ranged from 25 to 53 years (mean, 37
years). The duration of melasma varied from 4 to 8 years
(mean, 6.5 years). Family history of melasma was found in
19 (70%) patients. The most frequent precipitating factor
was the sun exposure followed by pregnancy. Eight patients
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Figure 3: Physicians Global Assessment in melasma patients with
niacinamide versus HQ.
3.1. Clinical Results. The onset average MASI score for
the HQ side was 4 (5% CI, 90.9–1.8) and 1.2 (95% IC,
0.8–1.6) after eight weeks (P<0.001). The initial MASI
score for the niacinamide side was 3.7 (95% CI, 2.9–
4.4) and 1.4 (95% CI, 3.3–4.7) at the end of the study
(P<0.001). The average decrease for HQ was 70% and
62% for niacinamide. This improvement was registered
using conventional photography (Figures 1 and 2)w i t hn o
perceptible diﬀerences between both sides.
The PGA rated the niacinamide side improvement as
excellent in three patients, good in nine, moderate in seven,
and mild in eight. The HQ-treated side was rated excellent
in seven, good in eight, moderate in six, and mild in six
patients (Figure 3). Data showed statistical signiﬁcance for
both treatments, HQ (P = 0.003), and niacinamide (P =
0.005).
Colorimetric assessment was performed initially and at
the end of the study; we evaluated the luminosity axis (L∗)
as well as the erythema axis (a∗). The lightening eﬀect of
HQ and niacinamide was apparent at 4 weeks of treatment,
whereas it was more evident at 8 weeks. Colorimetric
measures showed no statistical diﬀerences between both
treatments (Table 1). The erythema was more intense on
the side treated with HQ than with niacinamide, but it was
not statistically signiﬁcative. Infrared light thermography at
environmental temperature of 21◦C showed a diminished
temperatureof0.8◦Cinbothsidesaftertreatment.Therewas
no statistical diﬀerence between both treatments.
3.2. Histopathology Results. The biopsy samples were stained
with haematoxylin and eosin for general histology, Fontana
Masson to evaluate melanin pigment, and Wright-Giemsa
for metachromatic granules in mast cells. At baseline, we
found a moderate to severe degree of rete ridge ﬂattening
and epidermal thinning in 23 (85%) melasma biopsies.
Solar elastosis was present in all melasma samples. Mild
to moderate perivascular lymphohistiocytic inﬁltrates were4 Dermatology Research and Practice
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Figure 4: Epidermal pigmentation reduction. (a) Basal melasma skin biopsy, (b) skin biopsy posttreated with niacinamide. (Fontana
Masson, original magniﬁcation 40x). Below is shown the measured positive areas for melanin using a computer-assisted image analysis
program.
Table 1: Changes in MASI scores and colorimetric values for 4% HQ and 4% niacinamide-treated sides in 27 patients with melasma. Mast
cell counts and melanin expression initially and after treatment with niacinamide in 11 patients.
HQ Niacinamide
Onset 8wk P Onset 8wk P
MASI 4 (.9–1.8) 1.2 (.8–1.6) <0.001 3.7 (2.9–4.4) 1.4 (3.3–4.7) <0.001
L∗ axis 50.9 (49.1–52.6) 56 (54.6–57.4) <0.001 51.1(49.3–52.9) 56 (54.4–57.5) <0.001
a∗ axis 12.9 (12.3–13.5) 13.6 (12.6–14) 0.25 12.8 (12.1–13.5) 13.6 (12.7–14.5) 0.08
Mast cells/mm2 — — — 22 (15.1–28.9) 16.3 (11–21.7) 0.01
Stained Melanin (%) — — — 8.7 (8–9.5) 6 (5.1–6.9) <0.001
MASI score was calculated for each treated half-face.
No statistical diﬀerences were found in redness (a∗) for both treatments, before and after.
Final depigmentation Improvement (L∗) did not show diﬀerences between both treatments (P = 0.78). In parenthesis, conﬁdence Interval to 95%.
also present in all of them and moderate presence of
mast cells near elastotic areas in 11 (40%) patients. With
Fontana-Masson stained sections, the amount of melanin
was increased in all epidermal layers of melasma skin; we
observed pigment basal cells protruded into the dermis in 20
(74%) biopsies as informed before [12]. In the upper dermis,
we found scattered melanin in 19 (70%) melasma biopsies.
The features in the biopsies of nonexposed sun skin were
close to normal skin.
After8weeksoftreatment,theblindwasopenedinorder
to take a biopsy from the side treated with niacinamide. We
obtained 11 posttreatment biopsies for analysis. By means
of digital analysis of biopsies images, we could observe that
the amount of epidermal stained melanin was diminished
signiﬁcantly (P<0.0007). The average inﬂammatory
inﬁltrate of mast cells was reduced from 22 to 16 cells/mm2
(P = 0.01). Solar elastosis was also reduced, but no statistical
diﬀerences were present (Figure 4).
3.3. Spectrophotometry. Raman spectroscopy measurements
showed that the molecular structure of melanin was normal
and remained unaltered after exposure to niacinamide
since the measurements showed the characteristic peaks
of melanin previously published [11, 12]. Patients with
abnormal melanin could respond diﬀerently to treatment
and explain the variable success rate to HQ [11]. We wanted
to show that these patients were homogeneous in this aspect.
3.4. Side Eﬀects. Side eﬀects were present in the niacinamide
side in 5 patients (18%), compared to 8 patients (29%)Dermatology Research and Practice 5
for the HQ side. The most frequent side eﬀects were ery-
thema, pruritus, and burning. Most of them were mild for
niacinamide and moderated for HQ. On the niacinamide
side, erythema, pruritus, or burning was present in 2 (7%)
patients, and on the HQ side they were present in 5
(18%) patients. All these were reduced through continuous
treatmentinbothmodalities,asthea∗ colorimetricvaluedid
not show signiﬁcant changes for both treatments at the end
of the study.
4. Discussion
Melasma is a chronic and persistent hyperpigmentation,
representing a therapeutic challenge because of the high rate
of relapses. This work showed that niacinamide 4% is an
eﬀective agent for the treatment of melasma, as assessed
by objective methods and clinical evaluation. Our results
indicate that 4% niacinamide was eﬀective in approximate
40% of patients, showing outstanding clinical results. In the
posttreatment biopsies, we could observe that the amount of
epidermal melanin and inﬂammatory inﬁltrate was dimin-
ished signiﬁcantly, as well as solar elastosis although it was
not enough to get statistical diﬀerence. This insuﬃcient
antiaging eﬀect could be related to the short time of the
study; therefore, further clinical studies using niacinamide
for longer periods are warranted in this condition. We
observed that the evolution time of melasma did not aﬀect
the response to treatment. On the other hand, colorimetric
assessment showed no statistical diﬀerence between these
two treatments (P = 0.78). However, the lightening eﬀect
of HQ was evident as early as the ﬁrst month of treatment,
whereas with niacinamide was noted at second month. HQ
had the disadvantage of moderate adverse eﬀects in 18%
of patients, compared to milder in 7% with niacinamide.
Treatment with niacinamide showed no signiﬁcant side
eﬀects and was well tolerated; therefore, it could be used
for longer periods, as part of the initial hyperpigmentation
treatment and as maintenance drug. However, further trials
are required to assess the combination of this topical
drug with others agents and assess its additive eﬀects in
the treatment of melasma. The mechanism of action of
niacinamide in melasma could be through the reduction
of melanosomes transfer [3], photoprotection actions [4],
its anti-inﬂammatory properties [5], and a direct or related
antiaging eﬀects such as reduction of solar elastosis [9]. We
previously have described prominent inﬁltrates of mast cells
in the elastotic areas of melasma skin [1] and evidence of
damage to epidermal basal membrane, which could facilitate
the fall or the migration of active melanocytes and melanin
into the dermis allowing the constant hyperpigmentation in
melasma [13]. Due to these ﬁndings, we wanted to prove
an intervention capable of inducing modiﬁcations to these
atypical ﬁndings related in the pathogenesis of melasma, in
addition to modify the increased pigmentation. Therefore,
we propose niacinamide as an eﬀective, integral, and safe
therapeutic alternative in the melasma treatment, since it
not only reduces pigmentation and inﬂammation, but also
may reduce solar degenerative changes with minimal adverse
events.
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